{
    "pmcid": "8597880",
    "qa_pairs": {
        "What is the size range of nanobodies derived from the Camelidae family as mentioned in the study?": [
            "12 to 15 kDa",
            "10 to 13 kDa",
            "15 to 18 kDa",
            "20 to 25 kDa"
        ],
        "What resolution was the crystal structure of NIH-CoVnb-112 bound to the SARS-CoV-2 RBD determined at?": [
            "2.82 \u00c5",
            "3.10 \u00c5",
            "2.50 \u00c5",
            "3.50 \u00c5"
        ],
        "What was a noted limitation of the Syrian hamster model used in the study for evaluating NIH-CoVnb-112?": [
            "It has limitations in replicating the full spectrum of human COVID-19 disease.",
            "It cannot be used for testing prophylactic treatments.",
            "It does not allow for aerosolized delivery of therapeutics.",
            "It is not suitable for testing against multiple SARS-CoV-2 variants."
        ],
        "Which SARS-CoV-2 variants did NIH-CoVnb-112 demonstrate broad neutralization capability against?": [
            "Alpha, Beta, Gamma, and Delta",
            "Alpha, Beta, Mu, and Lambda",
            "Gamma, Delta, Mu, and Lambda",
            "Beta, Gamma, Omicron, and Lambda"
        ],
        "Which expression system was used to produce NIH-CoVnb-112, yielding 1.1 grams of purified nanobody from a 4-liter fermentation?": [
            "Pichia pastoris",
            "Escherichia coli",
            "Saccharomyces cerevisiae",
            "Mammalian cell culture"
        ]
    }
}